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Abstract
Type 1 diabetes (T1D) is an autoimmune disorder which develops when insulin-producing, 
pancreatic beta cells are destroyed by an aberrant immune response. Current therapies for T1D 
either treat symptoms or cause global immunosuppression, which leave patients at risk of 
developing long-term complications or vulnerable to foreign pathogens. Antigen-specific 
immunotherapies have emerged as a selective approach for autoimmune diseases by inducing 
tolerance while mitigating global immunosuppression. We previously reported SAgAs with 
multiple copies of a multiple sclerosis (MS) autoantigen grafted onto hyaluronic acid (HA) as an 
efficacious therapy in experimental autoimmune encephalomyelitis. While the immune response 
of MS is distinct from T1D, the mechanism of SAgAs was hypothesized to be similar and via 
induction of immune tolerance to diabetes antigens. We synthesized SAgAs composed of HA 
polymer backbone conjugated with multiple copies of the T1D autoantigen mimotope p79 using 
aminooxy chemistry (SAgAp79) or using copper-catalyzed alkyne-azide cycloaddition (cSAgAp79) 
chemistry. SAgAs constructed using the hydrolyzable aminooxy linkage, thus capable of releasing 
p79, exhibited physicochemical properties similar to the triazole linkage. Both SAgAp79 versions 
showed high specificity and efficacy in stimulating epitope-specific T cells. SAgAs can be taken 
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up by most immune cell populations but do not induce their maturation, and conventional dendritic 
cells are responsible for the brunt of antigen presentation within splenocytes. cSAgAp79 was more 
stimulatory than SAgAp79 both in vitro and in vivo, an effect that was ascribed to the peptide 
modification rather than the type of linkage. In summary, we provide here the first proof-of-
principle that SAgA therapy could also be applicable to T1D.
Graphical Abstract
Soluble Antigen Arrays have high specificity and efficacy in stimulating epitope-specific T cells, 
via T-cell receptors (TCRs), without directly promoting antigen presenting cell (APC) maturation.
INTRODUCTION
Type 1 diabetes (T1D) is an autoimmune disease that affects 2 in 1000 children and young 
adults.1 It is an aggressive and devastating form of diabetes caused by an aberrant immune 
response resulting in T cell-mediated destruction of insulin-producing beta cells in the 
pancreas. The cause for the development of T1D is still unknown but a combination of 
genetic and environmental factors increase the susceptibility of developing the disease.1, 2 
Advancements over the last few decades have led to new diagnostics tools, novel therapies 
for managing the disease, and the discovery of causative antigens. Recent research has 
aimed to deliver antigens in a format that induces antigen-specific tolerance.3, 4 Peptide-
based approaches are more selective than protein-based therapies for delivery of specific 
epitopes including mimotopes, which target T cell clones for which the natural epitope is not 
known or for which the known epitope is recognized with poor affinity. However, a 
drawback of the administration of peptides in vivo is their rapid diffusion and dilution, 
which may result in insufficient uptake on a per cell basis.
Many current approaches to antigen-specific immunotherapy (ASIT) exhibit characteristics 
similar to traditional vaccines. Vaccines are typically particulate and designed to initiate a 
directed adaptive immune response to specific antigens in order to elicit a robust 
“protective” immunological response upon re-challenge. Conversely, allergy shot therapies 
use soluble allergens to hyposensitize the immune response and establish tolerance.5 This is 
typically accomplished by delivering low doses of soluble antigens via subcutaneous (s.c) 
Leon et al. Page 2













injection over an extended period of time. Allergen-specific immunotherapies are known to 
hyposensitize immune responses, thus providing a potential benchmark for design of ASIT 
delivery systems for autoimmune diseases that has yet to be explored.6
SAgAs have been designed to bundle peptides / proteins together for more efficient uptake 
in vivo and, in some cases, achieve multivalent engagement of B cells.7, 8 In addition, SAgA 
uptake results in epitope presentation to targeted T cells in the absence of costimulation or 
proinflammatory cytokines, which may induce antigen-specific immune tolerance as a way 
to treat T1D. SAgAs are constructed using a hydrophilic linear polymer, hyaluronic acid 
(HA), grafted with multiple repeating epitopes from an autoantigen. Unlike particulate 
antigen delivery systems (i.e., nanoparticles, microspheres), SAgA size and solubility are 
more likely to drain from the injection site to the regional and systemic lymphoid tissues. 
Particle antigen delivery systems are also innately more ridged with fixed spacing and 
positioning of ligands, while SAgAs are flexible and capable of contouring the receptor 
spacing on the cell surface. Thus, SAgAs may improve receptor binding avidity as a result 
flexibility to allow for a greater number of interactions with the cell surface to bind and 
cluster receptors.9–16
We have previously reported utilizing soluble antigen arrays (SAgAPLP) constructed by 
conjugating multiple repeating copies of autoantigen proteolipid protein peptide 
(PLP139–151) to HA to induce tolerance in a multiple sclerosis (MS) mouse model known as 
experimental autoimmune encephalomyelitis (EAE). Both the hydrolyzable linked molecule 
SAgAPLP (i.e. releasable epitope) and nonhydrolyzable “clicked” molecule cSAgAPLP (i.e. 
non-releasable epitope) were able to cause B cell anergy, which was induced by BCR 
engagement and clustering in in vitro studies and suppressed EAE disease symptoms. 
cSAgAPLP showed enhanced efficacy when compared to SAgAPLP, possibly due the more 
stable covalent linkage in cSAgAPLP.7, 17–23
While the immune response of MS is distinct from T1D, the mechanism of SAgAs offers a 
general strategy for the delivery of autoantigens. Here, we tailored SAgA technology as an 
ASIT for T1D. We synthesized two versions of SAgAs composed of HA polymer backbone 
with multiple repeating copies of the T1D autoantigen-related mimotope p79 
(AVRPLWVRME) employing either a degradable or covalent linker. The p79 mimotope 
presented on the I-Ag7 MHC class II of non-obese diabetic (NOD) mice is recognized by 
CD4+ T cells from BDC2.5 T cell receptor (TCR) transgenic mice.24 These T cells have 
been identified as islet-infiltrating T cells25 and shown to also respond to the WE14 peptide 
from ChgA that has been modified by transglutaminase26 and to hybrid insulin peptides 
resulting from the fusion of insulin C peptide and WE14 (aka 2.5HIP).27 These T cells are 
pathogenic and rapidly initiate disease when transferred as activated cells in NOD mice or as 
naïve T cells in NOD.SCID mice.28, 29 Importantly, similar BDC2.5 T cell-targeting 
mimotope peptides have demonstrated potential to induce tolerance.30, 31 In addition, these 
endogenous p79-reactive CD4+ T cells are also readily identifiable in peripheral lymphoid 
tissues of NOD mice using MHC tetramers.27
The SAgAs were constructed via aminooxy chemistry (hydrolyzable: SAgAp79) or copper-
catalyzed alkyne-azide cycloaddition (CuAAC) chemistry (nonhydrolyzable: cSAgAp79) and 
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immune cell responses were elucidated (Scheme 1). The specificity and efficiency of T cell 
stimulation by these SAgAs was demonstrated by in vitro treatment of splenocytes from 
BDC2.5 versus NOD mice, and we identified conventional dendritic cells (cDCs) as the 
most efficient type of antigen-presenting cells (APCs) responsible for the presentation of 
SAgA-derived epitopes to T cells. We also observed that SAgAs do not induce APC 
maturation. In vivo, SAgAs efficiently distributed to different lymphoid tissues, inducing a 
similar response in draining and more distal lymph nodes, as well as in spleen. In summary, 
our results show that both types of SAgAs containing multiple copies of p79 can efficiently 
stimulate antigen-specific autoreactive T cells both in vitro and in vivo, and that in both 
settings, cSAgAp79 were more stimulatory than SAgAp79.
RESULTS & DISCUSSION
Analytical Characterization of Soluble Antigen Arrays
Hydrolyzable multivalent soluble antigen arrays (SAgAp79) capable of antigen release and 
the nonhydrolyzable (cSAgAp79) version were synthesized by conjugating approximately 9–
11 p79 peptides to a 16 kDa HA linear polymer. Seminal studies by Dintzis and others have 
suggested a multivalent linear polymer with a valency of 10–20 haptens and a molecular 
weight (MW) less than 100 kDa could induce immune tolerance.16, 32, 33 Characterization 
was completed using various analytical techniques. 1H NMR was utilized to confirm the 
successful CuAAC conjugation of all the starting materials to furnish cSAgAp79 (Figure 1). 
The peak at 7.8 ppm for cSAgAp79, highlighted in yellow, is consistent with previously 
reported proton chemical shift for a triazole proton. This peak was not seen in any of the 
starting materials since it can only form after the successful CuAAC reaction between the 
azide (HA-N3) and alkyne (hpP79). Resonance of both starting materials are seen in the final 
product highlighted in green (hpP79), purple (HA-N3), and blue (PEG3).
1H/13C Heteronuclear Single Quantum Coherence (HSQC) NMR spectroscopy was used to 
confirm the existence of resonances present in peptide sample hpP79 and HA-N3, which 
were carried over to the final dialyzed products cSAgAp79 and fcSAgAp79. These 
experiments affirm the complete absence of the terminal alkyne resonance from the terminal 
alkyne of the homopropargyl linker on the mimotope (δ(1H) ≈ 2.9 ppm, δ(13C) ≈ 70 ppm) in 
both the fluorescent and non-fluorescent SAgAp79 products (Figure 2). These experiments in 
combination with the 1H NMR confirm the final product contains only the conjugated 
peptide of nonhydrolyzable cSAgAs. 1H NMR was not used to confirm successful 
conjugation of hydrolyzable SAgAp79 due lack of material. Previous publication confirm 
RP-HPLP is sufficient to demonstrate successful conjugation.7, 8
Quantitative analysis of peptide conjugation efficiency was done using a RP-HPLC by 
measuring the decrease in peak area of the peptide throughout the course of the reaction 
(Figure S1: Supplementary Info). In CuAAC chemistry, Cu1+, which is a catalyst that allows 
the reaction to proceed, is generated in situ upon the addition of NaAsc, the reducing agent, 
to an inactive Cu2+ in solution. An aliquot of the reaction mixture was removed before the 
final NaAsc addition step, for HPLC analysis to establish a baseline response correlating to 
the molar excess of peptide used in the reaction. Thus, following the addition of NaAsc, any 
decrease in peak area of free alkyne-containing peptide (hpP79) was attributed to 
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conjugation. A small aliquot pre-NaAsc was taken from the reaction mixture as a control 
sample. hpP79 displayed <5% degradation (2.7%) at 37°C for 24 hours, demonstrating a 
minimal impact of peptide degradation on the accuracy of the analytical methodology. 
Quantitative analysis of peptide conjugation efficiency for cSAgAp79 was done by 
analyzing 1H NMR (Figure S2).
Bioconjugation optimization, which is required to achieve the desired peptide conjugation to 
HA-N3 (~10 peptides), was performed by testing various conditions such as buffer type, 
temperature, reactant concentrations, and molar excess of free peptide. From these 
observations, the desired peptide valency in cSAgAp79 (9–11 p79) and fcSAgAp79 (7:1; 
p79:FTUA) were identified. Similar to CuAAC reaction, the aminooxy reaction was tracked 
by measuring the decrease in peptide. Unlike the CuAAC, milder conditions were used, thus 
negligible degradation of peptide was seen via RP-HPLC. The reaction between aoP79 and 
HA was a one-step reaction resulting in the final desired peptide valence of SAgAp79 (10 
p79) and fSAgAp79 (8:2; p79:FITC) (See Table 1 for more information). The increased 
retention time of the bioconjugates following peptide conjugation (Figure S1) was consistent 
with increased product hydrophobicity. The hydrophilic polymer backbone comprises only 
~32% by mass of the SAgA but has a significant effect on hydrophilicity. Negligible 
degradation of peptide was seen via RP-HPLC. The reaction between aoP79 and HA was a 
one-step reaction resulting in the final desired peptide valence of SAgAp79 (10 p79) and 
fSAgAp79 (8:2; p79:FITC) (See Table 1 for more information).
To better understand the biophysical properties of the SAgAs, a few experiments were 
performed at physiologically relevant pH (7.4). Circular dichroism (CD) experiments were 
performed to evaluate the secondary structure of the bioconjugates (Figure 3A,B). CD 
revealed no significant secondary structure for the non-peptide components found in the 
SAgAs (data not shown), which include HA, HA-N3, triazole, FTA, and FTUA. The CD 
spectra of hpP79 and aoP79 both exhibited the presence of random coil, which is consistent 
with small peptide secondary structure in literature.34 However, the modified peptides 
secondary structures were different, possibly because of the differences in the 
hydrophobicity of the modification.
Both cSAgAs (Figure 3A) also exhibited a random coil structure but differ slightly from 
their parent peptide (hpP79). This may be due to the conjugation of peptides to HA resulting 
in loss of rotational freedom and decreased entropy of peptides in solutions. Both SAgAp79 
and aoP79 showed similar secondary structure to the cSAgAs (Figure 3B). The loss of the 
hydrophobic homopropargyl linker upon conjugation to HA-N3 makes the cSAgAs more 
hydrophilic, which may explain the similar secondary structure to both aoP79 and SAgAp79. 
fSAgAp79 did not follow this trend. Experiments studying the intrinsic fluorescence of the 
SAgA revealed no transition state change, and fcSAgAp79 showed a significant difference in 
intensity due to the conjugated fluorophore (Figure S2). Finally, DLS data (Table 1) revealed 
reasonable increases in size of SAgAs compared to starting materials. Interestingly, HA (16 
kDa) when compared to HA-N3 (24.5 kDa) was shown to be larger with the radii being 7.3 
nm and 6.5 nm respectively. Both SAgAs showed similar size at physiological pH (7.0) and 
high heterogeneity.
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Specificity of T cell Responses to SAgA-derived Epitopes
To validate the ability of the p79 epitopes grafted on SAgAs to elicit an antigen-specific T 
cell response, we cultured splenocytes from NOD and BDC2.5 mice with cSAgAp79 or with 
the corresponding ‘naked’ HA molecule. The specificity was demonstrated by both the lack 
of response of BDC2.5 T cells to HA and the lack of response of NOD T cells to cSAgAp79 
in terms of activation markers (Figure 4A,B) and cytokine production (Figure 4C–E).
Uptake of SAgAs by different Spleen Cell Populations
We then used FITC-conjugated SAgAs to compare the ability of different cell populations 
within the spleen to capture SAgAs (Figure S3). After up to 24h incubation in vitro, 
splenocytes were analyzed for FITC uptake. As early as 12h, all APC populations (B cells, 
macrophages/monocytes, pDCs and cDCs) but not T cells from both NOD and BDC 2.5 
splenocytes were found to take up SAgAs (Figures 5A and S4A,B). However, enhanced 
uptake by myeloid non-DCs (macrophages / monocytes / neutrophils) from BDC2.5 
splenocytes was observed as early as 12h as compared to myeloid non-DCs from NOD 
splenocytes. At later time point(by 24h), the uptake of SAgA was further enhanced for other 
cells including T cells (Figure 5B and S4A,B). Given that T cell activation was evident as 
early as 12h with BDC2.5 splenocytes (Figure 4), we hypothesized that antigen-specific T 
cell activation (possibly through cytokine release) stimulated other immune cells, leading to 
increase endocytosis. Indeed, the increased uptake of SAgA by BDC2.5 splenocytes was 
associated with increased expression of the maturation molecules CD40 and CD86 at 12–
24h (Figures 5C,D and S5) and increased cell size at 24h (Figures S4A vs S4B).
Importantly, SAgAs were not directly responsible for APC maturation because they had no 
effect on NOD splenocytes in terms of CD40/CD86 expression (Figures 5C,D and S5) and 
cell size (Figure S4A vs S4B). Thus, these SAgAs do not have inherent immunogenic 
adjuvant properties, a prerequisite for tolerance induction.
Presentation of SAgA-derived Epitopes by Spleen APCs
Given that most cell types were able to take up SAgAs provided at high dose (100 nM − 1 
μM), we then asked what APC subsets are most effective at processing and presenting 
SAgA-derived epitopes, using a limiting dose (1 nM) that would be more consistent with in 
vivo conditions. Following culture of NOD splenocytes with SAgAp79 or cSAgAp79 (no 
noticeable T cell response), the cells were sorted into 8 populations, as shown on Figure S6, 
and each purified population was cocultured with purified CD4+ CD25- T cells from 
BDC2.5 mice. Antigen-specific T cell stimulation was only detected with cDC subsets 
(Figure 6). Moreover, cSAgAp79 was more stimulatory than SAgAp79 (Figure 6). This was 
somewhat surprising as epitopes were not expected to be released as easily with the covalent 
link relative to the hydrolyzable link for processing.
Stimulatory Activity of SAgA Variants and their Corresponding Peptides in vitro
In the light of apparent stimulatory superiority of cSAgAp79 over SAgAp79, we conducted a 
titration of these two SAgAs along with their respective peptides, which had different 
modifications prior to grafting to HA. CD4+ T cells (10%; from BDC2.5 mice with 
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IL-10/GFP reporter) were diluted with non-specific T cells (90%; from NOD.CD45.2 mice) 
serving as internal negative controls for T cells (gating strategy shown on Figure S7A).
As negative control for antigen, we used SAgAp79k containing an immunologically inactive 
(“killed”) version of p79 with two amino acids permuted (p79k). Soluble peptides (aoP79 
used to make SAgAp79 and hpP79 used to make cSAgAp79) were compared with the non-
modified p79 and mixed together with the HA molecule used to make SAgA (HA with p79 
and aoP79 and HA-N3 with hpP79). Because each SAgA molecule bears ~10 peptides, we 
represented all concentrations as peptide-equivalent (e.g. 1 nM SAgA = ~10 nM peptide), 
and for free peptide / HA mixtures, we used 10-fold less HA than peptide to achieve the 
same relative amount of peptide as with SAgAs. The controls SAgAp79k and p79k+HA did 
not induce any T cell response (Figures 7 and S7), again highlighting the highly specific 
nature of the response. SAgAp79 and peptides p79 and aoP79 induced a similar T cell 
response (based on proliferation and surface markers) that was most evident at 1–10 nM, 
while cSAgAp79 and its peptide hpP79 were the most stimulatory, with T cell responses 
measurable at 10–100 pM (Figures 7A–E and S7).
We generally found that the free peptide was more stimulatory than its SAgA form at 
equivalent concentrations (Figure 7). However, at higher doses, SAgAs induced a greater 
PD-1 and IL-10/GFP upregulation than their respective free peptide (Figure 7E,F and S7). 
No significant stimulation was observed in bystander T cells (polyclonal T cells from 
NOD.CD45.2 mice; Figure S7H,I). The cytokine response required higher doses of peptide 
or SAgA (at least 10 nM for IL-10 and IFN-γ, and 100 nM for IL-2), and in this case, 
SAgAs were at least as stimulatory if not better than their corresponding free peptide (Figure 
7F–I). Overall, the results suggested that cSAgAp79 is more potent than SAgAp79 not 
because of the difference in release mode but rather because of the N-terminal modification 
of p79. Furthermore, both SAgAs promoted the upregulation of immune checkpoint 
receptors like PD-1 and Lag-3 in vitro (Figures 7D,E and S7H), which may help predispose 
the targeted T cells to tolerance induction by their ligands.
Antigen Biodistribution and their Engagement with Antigen-Specific T Cells in vivo
To validate the in vitro specificity and stimulatory capacity of SAgA variants in inducing T 
cell responses, we studied their biodistribution in various lymphoid tissues in vivo, based on 
engagement of antigen-specific T cells. To that end, antigen specific CD45.1+ CD4+ CD25- 
T cells were purified from BDC2.5 TCR transgenic mice and adoptively transferred into 
recipient CD45.2 mice. Analysis of T cell responses by FCM revealed that both SAgAp79 
and cSAgAp79 induced effective antigen-specific T cell responses (expansion and 
proliferation of donor specific T cells) in all lymphoid tissues investigated after s.c. 
injection, suggesting drainage and presentation of SAgA-derived peptides to T cells in broad 
anatomical locations (Figure 8 and S8A,B). In contrast, there was no change in the 
percentage of recipient CD4+ T cells (CD45.2+ CD4+ T cells) among all the three groups 
(Figure S8C), highlighting specificity of both SAgA variants. Consistent with the in vitro T 
cell responses results, in vivo expansion of antigen-specific T cells was higher in mice 
treated with cSAgAp79 as compared to SAgAp79 or HA treated mice in all lymphoid tissues 
investigated (Figure 8A,B). Moreover, while both SAgA variants induced proliferation of 
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donor CD4+ T cells, those responding to cSAgAp79 proliferated to a greater extent 
(Fig.S8A,B).
To further confirm the stimulatory activity of each SAgA variant and the location of T cell 
responses in a more physiological setting in vivo, we analyzed p79-reactive tetramer+ cells 
in PLN and spleen after s.c. injection. Both variants of SAgA induced antigen-specific T cell 
responses (upregulation of CD44 among tetramer+ CD4+ T cells) as compared to HA 
control in both tissues, suggesting effective drainage of SAgAs into PLN and spleen for 
presentation by APCs to T cells. However, cSAgAp79 induced higher percentage of tetramer
+ CD44hi CD4+ T cells as compared to SAgAp79 or HA control (Figure 9A–C). We repeated 
the treatment for a longer period of time (~1 month with 3 weekly injections), and while 
both SAgAs induced significant number of tetramer+ CD4+ T cells (with increased CD44 
expression) in pooled lymph nodes and spleen, cSAgA again was found to be more 
stimulatory (Figure 9D,E and S9A). Treatments with SAgAs had no effect on non-specific T 
cells (Figure S9B–E). Altogether, the data suggest that both variants of SAgA distribute 
widely through regional and distal lymphoid tissues and elicit antigen-specific T cell 
responses, which were of greater magnitude in the case of cSAgA.
Both hydrolyzable and nonhydrolyzable SAgAs were characterized and evaluated in vitro as 
therapeutic agents to target diabetogenic BDC2.5 T cells as representative autoreactive T 
cells in the NOD mouse model of T1D. Biophysical properties of both versions of non-
fluorescent SAgA varied slightly. CD spectra for both hydrolyzable SAgAp79 and 
nonhydrolyzable cSAgAp79 were shown to be similar to the aoP79 modified mimotope. 
Neither appeared to have any transition state when tested via a temperature fluorescent 
gradient.
Our in vitro immunoassays demonstrated that SAgA-derived epitopes were efficiently 
presented to specific T cells. T cell responses were generally greater with soluble peptide 
because of the high local concentration at which some free peptide may directly bind to 
MHC-II via spontaneous peptide exchange, whereas SAgAs likely require endocytosis, 
degradation and processing before loading onto MHC. We initially postulated that the 
distinct peptide grafting chemistries between SAgAp79 and cSAgAp79 would influence their 
immunological properties. Indeed, the ability of SAgAs to bring in bundled peptides inside 
the cells and release them should be affected by the balance of extracellular versus 
endosomal degradation. Excessive extracellular degradation could reduce the overall peptide 
uptake while insufficient endosomal degradation could limit peptide loading onto MHC. 
Hydrolyzable SAgAs are expected to release their peptide cargo under the endosome’s low 
pH, while the covalent linker is not expected to be broken down by any known enzymes. 
Both SAgAs and cSAgAs are susceptible to degradation at the level of the HA backbone by 
extracellular and endolysosomal hyaluronidases. Thus, differences in stimulatory activity 
may be determined by how much peptide is effectively taken up and loaded on MHC. 
However, when comparing the stimulatory activity of two modified peptides used to produce 
these two forms of SAgAs, namely the aminooxy and alkyne versions, we observed that the 
alkyne form of the peptide was also significantly more stimulatory. While the N-terminal 
aminooxy residue did not seem to have any effect on T cell stimulation relative to the 
unmodified p79 peptide, the N-terminal alkyne could possibly alter the interaction with the 
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MHC-II molecule such that the peptide’s orientation is changed and interaction with the 
BDC2.5 TCR is enhanced. Interestingly, both hpP79 and cSAgAp79 are more stimulatory, 
suggesting that both the alkyne motif (C≡C) and the C2N3 cycle resulting from reaction with 
azide would have the same effect on tweaking the overall epitope conformation.
More studies will be required to understand this surprising superior stimulatory effect of 
both the alkyne-modified peptide and its SAgA and evaluate their therapeutic efficacy in 
preclinical studies in T1D models. While in vitro stimulation was expected to favor soluble 
peptides for the reasons provided above, it is expected that SAgAs will be more stimulatory 
than free peptides in vivo due to reduced diffusional loss, greater peptide uptake and 
improved lymph node drainage. More stimulatory SAgAs may have utility to achieve good 
T cell engagement with lower dose. Indeed, most autoreactive T cells have low TCR affinity, 
and antigen-specific therapies, unlike conventional vaccines, do not contain adjuvants that 
boost APC-T cell interactions via upregulation of MHC, costimulatory and adhesion 
molecules. Thus, enhancing epitope recognition may be required to improve engagement of 
autoreactive T cells, and mimotopes with better affinity than native peptides can achieve 
better induction of tolerance in vivo.35
CONCLUSION
ASIT may one day offer a means to treat autoimmune diseases by using autoantigens to 
induce immune tolerance. To date, formulations of autoantigens have been minimally 
effective in preventing or treating diseases such as T1D. SAgAs offer a new approach 
wherein multiple copies of epitopes or whole autoantigens can be grafted onto HA to 
promote the desired immune responses in draining lymphoid organs or in tissues containing 
autoreactive immune cells, such as T and B cells. In this work, SAgAs displaying multiple 
copies of the T1D autoantigen mimotope p79 were linked to HA using aminooxy chemistry 
(i.e. releasable mimotope, SAgAp79) or using copper-catalyzed alkyne-azide cycloaddition 
chemistry (i.e. non-releasable mimotope, cSAgAp79). Both versions showed high specificity 
and efficacy in stimulating epitope-specific T cells without directly promoting APC 
maturation. Conventional dendritic cells were predominantly responsible for antigen 
presentation within splenocytes derived from NOD mice. The cSAgAp79 was able to 
stimulate cognate T cells more potently than SAgAp79. The specificity of SAgAs displaying 
the p79 mimotope provide here the first proof-of-principle that SAgA therapy could be 
applicable to T1D prevention or therapy.
METHODS
Chemical Synthesis
N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC), 2-(N-
morpholino)ethane-sulfonic acid sodium salt (MES), tris(3-
hydroxypropyltriazolylmethyl)amine, sodium ascorbate (NaAsc), and Propargyl-N-
hydroxysuccinimidyl ester were purchased from Sigma-Aldrich (St. Louis, MO) and used as 
received without further purification. Hyaluronic acid sodium salt (MW 16 kDa) was 
purchased from Lifecore Biomedical (Chaska, MN). 11-azido-3,6,9-trioxaundecan-1-amine 
(NH2-PEG3-N3), N-hydroxysuccinimide, Copper (II) sulfate pentahydrate (CuSO4 • 5H2O) 
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was purchased from Acros Organics (Geel, Belgium). Alkyne-functionalized peptide bearing 
an N-terminal 4-pentynoic acid (homopropargyl, hp) modification, hpP79 (hp-
AVRPLWVRME-OH), aoP79 (aminooxy-AVRPLWVRME-OH) and an immunologically 
killed version (with two permuted amino acids) AVPRLWVRME (p79k) were obtained from 
Biomatik USA, LLC (Wilmington, DE).
Synthesis and Labeling of Soluble Antigen Arrays
Hydrolyzable SAgAp79 and its fluorescein isothiocyanate (FITC)-labeled version 
(fSAgAp79), nonhydrolyzable cSAgAp79 and its fluorescein thiourea-labeled (fcSAgAp79) 
were synthesized and characterized as previously reported. Peptide conjugation was 
determined through gradient reverse-phase analytical high-performance liquid 
chromatography (RP-HPLC).
Synthesis of Fluorescein Thiourea Alkyne (FTUA)
Synthesis of 2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-5-(3-(prop-2-yn-1-yl)thioureido) 
benzoic acid (fluorescein thiourea alkyne; FTUA; Scheme 1A) was adapted from Meng et 
al.36 Triethylamine (75 μL, 0.514 mmol) was added to a mixture of Fluorescein 
isothiocyanate (FITC) (200mg, 511.4 μmol) and 1-amino-11-azido-3,6,9-trioxa-undecane 
(131mg, 119.09 μL, 0.616 mmol) in DMSO (1 mL) and the mixture was stirred for 2 h at 
room temperature in the dark. The reaction mixture was then frozen at −20°C and 
lyophilized to afford a red oil. The crude product was dissolved in DMSO and purified by 
preparative RP-HPLC (Waters XBridge C18, 5 μm, 10×250 mm, linear gradient from 5–95% 
MeCN (+ 0.05% TFA) in H2O (+ 0.05% TFA) over 20 minutes, detection at 280 nm) to give 
the final product (176.5 mg, 77%) as an orange-yellow powder; 1H NMR (500 MHz, 
DMSO-d6) δ 7.82–7.78 (m, 1H), 7.83–7.77 (m, 2H), 7.05–7.00 (m, 1H), 6.42–6.26 (m, 6H), 
7.11 (d, J = 2.4 Hz, 1H), 7.08 (d, J = 2.4 Hz, 1H), 7.03 (s, 1H), 7.00 (s, 1H), 6.97 (d, J = 2.4 
Hz, 1H), 3.65 (q, J = 7.14, 7.06, 7.06 Hz, 2H), 3.77 (d, J = 2.5 Hz, 2H), 2.70–2.63 (m, 8H), 
2.66 (t, J = 2.5, 2.5 Hz, 1H)1.08 (t, J = 6.95, 6.95 Hz, 12H): HRMS expected [M+H]+: 
445.0853, found: 445.0858.
Synthesis of Azide Functionalized Hyaluronic Acid (HA-N3)
Synthesis of HA-N3 (Scheme 1A) was adapted from Hu et al and Di Meo et al.36, 37 Sodium 
hyaluronate (93.9 μmol, 16 kDa average MW) was added to a 250 mL round bottom flask 
with stir bar, followed by 100 mL of 50 mM MES buffer (pH = 4.0). The mixture was stirred 
until in solution (~15 minutes) before EDC (23.1 mmol) was added neat, then N-
hydroxysuccinimide (18.8 mmol) added neat. The mixture was stirred for 5 minutes before 
H2N-PEG3-N3 (4.51 mmol) in 20 mL MES buffer was added. The solution was then stirred 
for 24 hours at room temperature before being dialyzed in 6–8 kDa cutoff dialysis tubing 
against 4.5 L of 1.0 M NaCl solution for 24 hours, then 4.5 L of deionized water (4 × 12 
hours). The volume in the bag was then transferred to vials, frozen, and lyophilized to yield 
a white powder (1.61 g, 95.0%).
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Synthesis of Nonhydrolyzable Soluble Antigen Arrays (cSAgAs p79)
HA-N3 (1.6 μmol) was added as a 30 μM solution in phosphate buffer (pH= 7.0) to a 250 
mL round bottom flask with stir bar. Then hpP79 (40 μmol) was then added as a 3.52 mM 
solution in phosphate buffer (pH= 7.0), followed by a premixed solution of THPTA (70 
μmol) and CuSO4 • 5H2O (14.5 μmol) in phosphate buffer (pH= 7.0). The solution was 
allowed to stir for 1–2 minutes before a 100 μL aliquot was removed for HPLC analysis. 
NaAsc (295 μmol) was then added to the reaction mixture as a 100 mM solution phosphate 
buffer (pH= 7.0). The reaction was allowed to 24 hours at room temperature. Additional 100 
μL aliquots were removed throughout the course of the reaction to determine the extent of 
conjugation. Then the reaction solution was quenched by adding 0.5 mL of 50 mM EDTA, 
then transferred to 6–8 kDa dialysis tubing and dialyzed against 4.5 L of 1.0 M NaCl (3 × 8 
hours), then 4.5 L of deionized H2O (6 × 8 hours). The volume in the bag was then 
transferred to vials, frozen, and lyophilized.
Synthesis of Nonhydrolyzable Fluorescent Soluble Antigen Arrays (fcSAgAs p79)
HA-N3 (2.0 μmol) was added as a 30 μM solution in phosphate buffer (pH= 7.0) to a 250 
mL round bottom flask with stir bar. Then hpP79 (40 μmol) was then added as a 3.52 mM 
solution in phosphate buffer (pH= 7.0), followed by fluorescein thiourea alkyne (4 μmol), 
and then by a premixed solution of THPTA (70 μmol) and CuSO4 • 5H2O (14.5 μmol) in 
phosphate buffer (pH= 7.0). The solution was allowed to stir for 1–2 minutes before a 100 
μL aliquot was removed for HPLC analysis. NaAsc (295 μmol) was then added to the 
reaction mixture as a 100 mM solution phosphate buffer (pH= 7.0). The reaction was 
allowed to 24 hours at room temperature. Additional 100 μL aliquots were removed 
throughout the course of the reaction to determine the extent of conjugation. Then the 
reaction solution was quenched by adding 0.5 mL of 50mM EDTA, then transferred to 6–8 
kDa dialysis tubing and dialyzed against 4.5 L of 1.0 M NaCl (3 × 8 hours), then 4.5 L of 
deionized H2O (6 × 8 hours). The volume in the bag was then transferred to vials, frozen, 
and lyophilized.
Hydrolyzable Soluble Antigen Arrays (SAgAp79)
Single-step grafting of aminooxy peptides to 16 kDa HA was performed as described 
previously.22 Briefly, HA was dissolved in 20 mM acetate-buffered solution (pH 5.5 ± 0.1) 
and each aminooxy reactive peptide was added simultaneously. After addition of the 
peptides, the reaction solution was adjusted to pH 5.5 ± 0.1 and stirred at 500 rpm using a 
magnetic stir bar for 16 h at room temperature. The samples were then transferred to dialysis 
bags (MWCO 6000–8000 Da, Spectrum Laboratories, Inc., Rancho Dominguez, CA) and 
dialyzed against 2 L of deionized water for 24 h, with dialysis water exchanged every 6 h to 
remove unreacted peptides and residual buffer. After dialysis, the dialysate was frozen at 
−70°C and lyophilized.
Hydrolyzable Fluorescent Soluble Antigen Arrays (fSAgAp79)
Single-step grafting of aminooxy peptides to 16 kDa HA was performed as described 
previously.22 Briefly, HA was dissolved in 20 mM acetate-buffered solution (pH 5.5 ± 0.1) 
and aminooxy reactive peptide and FITC were added simultaneously. After addition of the 
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peptides, the reaction solution was adjusted to pH 5.5 ± 0.1 and stirred at 500 rpm using a 
magnetic stir bar for 16 h at room temperature. The samples were then transferred to dialysis 
bags (MWCO 6000–8000 Da, Spectrum Laboratories, Inc., Rancho Dominguez, CA) and 
dialyzed against 2 L of deionized water for 24 h, with dialysis water exchanged every 6 h to 
remove unreacted peptides and residual buffer. After dialysis, the dialysate was frozen at 
−70°C and lyophilized.
Analytical Characterization of Click Soluble Antigen Arrays
NMR spectra were collected on a Bruker Avance AVIII 500 MHz spectrometer equipped 
with a dual carbon/proton cryoprobe, all samples were dissolved in 600 μL of D2O for 
examination. MestReNova 11.0 was used for NMR data analysis.
RP-HPLC analysis was done using a Waters Alliance HPLC system equipped with either a 
dual wavelength UV/Vis detector or diode array detector. For the quantitative determination 








where Ncon = number of conjugated peptides per backbone, npep = moles of peptide used in 
reaction, nHA = moles of HA-N3 used in reaction, Vpre = total reaction volume before 
NaAsc is added, Vsam = volume of “pre-NaAsc” sample removed from reaction mixture, PAt 
= measured peak area of peptide at time t, PAstart = measured peak area of free peptide 
before NaAsc is added to the reaction. General chromatographic conditions employed a 
Waters XBridge C4, 3.5 μm, 300 Å stationary phase under ion pairing (0.05% TFA in H2O 
and MeCN) mobile phase conditions, utilizing a linear elution gradient (5–70%) with 
detection at 214 nm.
Biophysical Characterization
Determination of peptide concentrations was done with ε280 nm (3 mL⋅g−1⋅cm−1) for p79. 
For derivatized polymers, the concentrations were determined on a total peptide basis (the 
same absorbance) so that the total concentration of p79 is unchanged. Other polymers and 
fluorescence concentrations were determined by weight.
Far UV Circular Dichroism (CD)
Far UV Circular Dichroism was performed using an Applied Photophysics Chirascan 
equipped with a 6-cell holder (Applied Photophysics, Leatherhead, UK).38 Proteins were at 
concentrations of ~0.1 mg/ml, in phosphate buffer (pH= 7.0), in a 1-mm quartz cell. CD was 
measured from 195 – 250 nm and using a 1 nm step size with a two second integration time 
at each step. Finally, corresponding buffers were subtracted for each sample.
Dynamic Light Scattering (DLS)
Dynamic light scattering was performed using a DynaPro Plate Reader (Wyatt Technology, 
Santa Barbara, CA).39 Incident light was detected in a backscattering configuration and 
analyzed with an autocorrelator. 20 μL of sample, in phosphate buffer (pH= 7.0), was placed 
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in a clear-bottomed 384 well plate and read at 20°C. Samples were measured 5 times with a 
15 second acquisition time. Autocorrelation functions were fit using cumulant analysis and 
intensity averaged values are reported. Errors are reported as standard deviation of 3 
replicates.
Malvern Zetasizer DLS
Dynamic light scattering was performed using a Malvern Zetasizer. Samples (0.2 mg/mL in 
phosphate buffer pH= 7.0) were placed in custom quartz cuvettes and illuminated with a 632 
nm laser, back-scattered light was collected at a 173° degrees. DLS autocorrelation curves 
were fit using the CONTIN algorithm and sizes are reported as number average diameter.
Intrinsic Fluorescence Spectroscopy
Intrinsic fluorescence was measured as described previously using custom fluorescence plate 
reader (Fluorescence Innovations, Minneapolis, MN).38 Briefly, a 285 nm laser was used to 
excite samples and fluorescence was collected at 180° after passing through a 310 nm 
longpass filter to block excitation light. A prism dispersed light onto a CCD to quantify the 
fluorescence as a function of wavelength. 10 μL of sample, in phosphate buffer (pH= 7.0), 
was placed in a 384 well plate and covered with 2 μL of silicon oil to prevent sample 
evaporation. The fluorescence was measured from 10 to 90°C with a step-size of 1.25°C and 
an equilibration step of 2 min between each temperature. The total intensity from 300 to 400 
nm was averaged for each temperature. Error bars represent the standard deviation of 4 
replicates.
Mice
NOD (Jax #001976), BDC2.5 T cell receptor (TCR) transgenic mice (Jax #004460) and 
NOD.CD45.2 congenic mice (Jax #014149) were purchased from The Jackson Laboratory. 
NOD. IL-10/GFP (“Tiger”) mice were kindly provided by Pere Santamaria40. 
BDC2.5.IL-10/GFP mice were produced by crossing NOD.IL-10/GFP mice with BDC2.5 
mice. All mice were bred and maintained in the Columbia Center for Translational 
Immunology’s animal barrier facility. Both male and female mice between 6–12 weeks of 
age were used as donors for the splenocytes used in all experiments. All mice used in this 
study were handled according Columbia University Institutional Animal Care and Use 
Committee recommendations and approved protocols.
T cell Stimulation Assay
Splenocytes from NOD and NOD.BDC2.5 mice were subjected to ACK (Ammonium-
chloride-potassium) buffer to lyse red blood cells, filtered through a 70 μm cell strainer and 
resuspended into complete RPMI medium (containing 10% FBS, 50 IU/ml penicillin, 50 
μg/ml streptomycin, 2 mM L-glutamine, 0.1 mM non-essential amino acids, 1 mM sodium 
pyruvate and 0.05 mM 2-Mercaptoethanol). The splenocytes were counted and labeled with 
a violet cell proliferation dye eFluor450 (VCPD) (10 μM for 15 min, eBioscience). VCPD-
labeled splenocytes were cultured at 2×105 cells/well with or without 100 nM of SAgAp79, 
cSAgAp79 or HA in U bottom 96-well plates in triplicates. After 3 days of culture in a 
humidified CO2 incubator at 37°C, the supernatants were collected and kept at −20°C for 
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cytokine analysis. The splenocytes were harvested and stained with antibodies to CD4, 
CD25, CD44 and CD69 (Biolegend) and CD4+ T cell responses were analyzed by flow 
cytometry (FCM) on BD Fortessa. From collected supernatants, cytokine concentrations 
(IL-2, IL-10 and IFN-γ) were measured by ELISA (MAX kits, Biolegend) according to 
manufacturer guidelines.
Cellular Uptake
Splenocytes were isolated from NOD or BDC2.5 mice as above, and cultured at 2×105 cells 
per well (U bottom 96-well plates) in complete RPMI medium with or without fcSAgAp79 at 
0.1–1μM final concentration in humidified CO2 incubator at 37°C. Cells were harvested at 
12 or 24h time points, washed twice to remove unbound fcSAgAp79 and stained with 
antibodies to CD45, B220, CD11c, CD11b, CD8a, F4/80, CD40 and CD86 (Biolegend). 
Samples were then analyzed on Fortessa for fcSAgAp79 uptake by various cell types. 
Moreover, expression of costimulatory molecules CD86 and CD40 was measured to assess 
activation / maturation of various APCs.
APC Subset-specific Antigen Presentation
Splenocytes from NOD mice were prepared as above and cultured at 2×105 cells/well with/
without SAgAp79 or cSAgAp79 at 1 nM concentration (limiting low dose to better identify 
the most efficient APCs). After 24h, the cells were harvested, washed twice, stained with 
antibodies against CD8, B220, CD11c, CD11b, CD45 and Gr-1 and sorted into eight 
populations (BD Influx sorter). Finally, 103 sorted cells from each sorted population were 
co-cultured with 50,000 purified T cells/well (10% CD4+ CD25- T cells from BDC2.5 mice 
and 90% CD4+ CD25- and CD8+ T cells from NOD.CD45.2 mice) for 4 days. T cell 
purification was performed with MoJoSort magnetic cell separation kits (mouse CD4 T cell 
and CD3 T cell isolation kits, respectively, both supplemented with biotinylated anti-CD25). 
The analysis of T cell response was performed by FCM as described above.
Peptide and SAgA Titration
Splenocytes from NOD.BDC2.5.IL-10/GFP and NOD.CD45.2 mice were prepared as 
described above, labeled with VCPD and mixed (10% and 90% respectively). The 
splenocytes were co-cultured (2×105 total cells/well) in the presence/absence of titrated 
SAgAp79 or cSAgAp79 or their corresponding free peptide at 10-fold serial dilutions ranging 
from 10pM to 1μM concentrations. After 3 days of culture, the supernatants were removed 
for cytokine analysis and kept at −20°C. The splenocytes were collected, stained with 
antibodies to CD45.1 (to distinguish antigen-specific CD4+ T cells from bystander CD45.2+ 
T cells), to CD25 and CD44 (activation) and to Lag-3 and PD-1 (immune checkpoint 
markers) and analyzed by FCM. Secreted cytokines (IL-2, IFN-γ and IL-10) in stored 
supernatants were quantified by ELISA (as above).
Assessing T Cell Responses in Vivo Using an Adoptive Transfer Model
CD45.1+ CD4+ CD25- T cells were isolated from pooled lymph nodes and spleen of female 
BDC2.5 donor mice and purified using the MojoSort™ Mouse CD4 T Cell Isolation Kit 
(Biolegend) supplemented with biotinylated anti-CD25. One million VCPD labeled 
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CD45.1+ CD4+ CD25- T cells/mouse were injected into female recipient CD45.2 NOD 
mice intravenously. The recipient mice were randomly distributed through each group and 
were treated with HA (control), SAgAP79 or cSAgAP79 via subcutaneous injection of 0.5 
nmol in 200ul on the neck fold. Five days after treatment, CLN, ALN, PLN and spleen were 
separately collected and single cell suspensions were prepared. The cells were stained with 
antibodies to CD4, CD45.1 and CD44 and T cell responses were analyzed by FCM on BD 
Fortessa.
Analysis of T Cell Response in Vivo Using MHC-tetramer
Female NOD mice were randomly distributed for each group and treated with HA (control), 
SAgAp79 or cSAgAp79 at 2.5 nmol dose via subcutaneous injection on day 1 and day 3 on 
the neck fold. On the 6th day after treatment, PLN and spleen were collected from all the 
recipient mice for in vivo endogenous T cell response analysis. Similarly, another cohort of 
NOD mice was treated with HA, SAgAp79 or cSAgAp79 at 2.5 nmol via s.c. subcutaneous 
injection with weekly dosing for three weeks. On the 26th day after treatment, all the three 
lymph nodes (ALN, CLN and PLN) were pooled together and spleen was separately 
collected from all mice. Lymphoid cells and splenocytes were isolated and stained with 
p79/2.5 mimotope MHC tetramer and antibodies to CD4, and CD44. Both tetramer+ and 
tetramer- CD4+ T cells were analyzed by FCM on BD Fortessa.
Statistical and Data Analysis
GraphPad Prism was used to perform statistical analysis including sigmoidal nonlinear 
regression, ordinary one-way or two-way analysis of variance (ANOVA), and unpaired t-test. 
ANOVA was followed by Tukey’s or Sidak’s post-hoc test, where appropriate. The threshold 
for statistical significance was set to p<0.05. FCM data were analyzed with FCS Express 6.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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1H NMR spectra of starting materials and the reaction product. Resonances from the peptide 
starting materials are present in the final compound cHAP79. A new peak only found in the 
product is highlighted in light yellow.
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HSQC NMR spectra of starting materials and the product fcSAgAp79 and cSAgAp79. 
Resonances from the peptide starting materials are present in the final compounds for both 
cSAgAp79 and fcSAgAp79. The alkyne peak found only hpP79 is not found in any of the 
products, which implies complete no residual unconjugated p79.
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Far-UV Circular Dichroism of cSAgAp79 (A) and SAgAp79 (B)
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Antigen-specific CD4+ T cells responses to cSAgAp79 in vitro. Representative plots (A) and 
summary of triplicates samples (B) showing upregulation of CD25, CD44 and CD69 in 
CD4+ T cells from BDC2.5 mice as compared NOD mice after 12h of culture. (C-E) 
Cytokine secretion at 12h and 24h of culture: IL-2 (C), IL-10 (D) and IFN-γ (E). The values 
are given as mean ± SD (n=3 technical replicates).
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Uptake efficiency of fcSAgAp79 (1 μM) by different APCs at 12h (A) and 24h (B) time 
points and upregulation of costimulatory molecules CD40 (C) and CD86 (D) at 24h in 
splenocytes from BDC2.5 as compared to NOD or untreated control splenocytes. Control 
cells from NOD mice are not shown (comparable to BDC2.5 control). The values are given 
as mean ± SD (n=3 technical replicates) and the data are representative of two experiments 
performed with fcSAgAp79, and experiments performed with FITC-conjugated SAgAp79. 
MMN: monocytes, macrophages, neutrophils.
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Conventional DCs (cDC1 and cDC2) most efficiently present epitopes from SAgA to CD4+ 
T cells as compared to other APCs. Representative dot plots depicting proliferation and 
CD25 upregulation by antigen-specific BDC2.5 CD4+ T cells (A), and summary bar graphs 
of BDC2.5 CD4+ proliferation (B) and upregulation of CD25 (C) and CD44 (D). The values 
are given as mean ± SEM (n=3 culture replicates).
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Dose-response curves of BDC2.5 CD4+ T cell responses (gated on CD45.1+ cells) induced 
by SAgAp79 and cSAgAp79 compared to their respective peptide aoP79 and hpP79 after 3 
days in vitro culture: proliferation based on VCPD dilution (A), upregulation of CD25 (B), 
CD44 (C), Lag-3 (D), PD-1 (E), and IL-10/GFP (F), secretion of IL-10 (G), IL-2 (H) and 
IFN-γ (I). The values are given as mean ± SD (2–3 culture replicates per experiment). Data 
are representative of 2–3 experiments for each molecule with at least two batches tested for 
most molecules showing comparable results. In other experiments, the free peptide was 
consistently more potent than its corresponding SAgA.
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In vivo expansion of transferred BDC2.5 CD4+ T cells in response to SAgAp79 and 
cSAgAp79 as compared to HA control in: axillary lymph nodes (ALN), cervical lymph 
nodes (CLN), pancreatic lymph nodes (PLN) and spleen, 5 days after s.c. injection (0.5nmol 
each). (A) Representative dot plots showing expansion of transferred antigen-specific CD4+ 
T cells. (B) Percentage of donor CD45.1+ cells among total CD4+ T cells. (C) Expansion of 
donor CD4+ T cells in PLN of HA-treated mice is the default response of these T cells to 
islet-derived endogenous antigens due to close proximity to islets. Bar graphs show the 
mean ± SD (n=3 mice). Student’s t-test was used to determine the p values.
Leon et al. Page 26














In vivo p79-specific T cell responses to SAgAp79 and cSAgAp79 as compared to HA control 
analyzed with 2.5/p79 MHC tetramer. (A) Representative dot plots showing tetramer+ T 
cells and their expression of activation marker CD44 (gated on CD4+ T cells) in PLN and 
spleen, three days after two s.c. injections, three days apart. The percentage of CD44hi cells 
among tetramer+ CD4+ T cells is indicated in red on each plot. (B,C) Increased frequency 
of p79-specific endogenous CD4+ T cells (B), and percentage of CD44hi cells among them 
(C) under the same conditions as (A). (D,E) Increased frequency of p79-specific 
endogenous CD4+ T cells (D), and percentage of CD44hi cells among them (E) in pooled 
lymph nodes and spleen, three days after 3 weekly s.c. injections. Bar graphs show the mean 
± SD (n=3mice). Student’s t-test was used to determine the p values.
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Synthesis of SAgA and cSAgA components and molecules: (A) Alkyne-functionalization of 
fluorescein isothiocyanate; (B) Structures of homopropargyl-modified peptide (hpP79) and 
aminooxy-modified peptide (aoP79); (C) Hydrolyzable soluble antigen array (SAgA); (D) 
“Click” soluble antigen array (cSAgA)
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Table 1.
Peptide molar conjugation of hydrolyzable and click conjugates, as determined by RP- HPLC
a
. Dynamic light 
scattering (DLS) of SAgAs and components.
Sample Approx. MW (kDa)




P79: HA DYE: HA Radius (nm) %Polydispersity
1.335 0 0 0.82 ± 0.02 0.14
1.3287 0 0 0.82 ± 0.02 0.04
1.3287 0 0 NA NA









f 0 9.26 ± 1.45e 0.85e
33.8 7 1 NA NA




30.1 8.2 1.8 NA NA
30.1 10 0 NA NA
a
Results are an average of triplicate injections from a single batch preparation. In the molecule schematics, dotted lines represent hydrolyzable 
oxime linker chemistry while solid lines represent nonhydrolyzable ‘click’ linker chemistry.
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b
Calculated from RP-HPLC data. MW, molecular weight.
c
HA, hyaluronic acid; p79
d
DLS data were collected in triplicate
e
Malvern Zetasizer DLS were collected in quadruplicate
f
The average molar ratio determined using HPLC was used when calculating dose.
NA: not assessed
 represents fluorescent dye.
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